BioInformant

Your Global Leader in Stem Cell Market Research

L7 Informatics, Data Management and Process Automation Solutions for Cell and Gene Therapy Companies

By

L7 InformaticsHeadquartered in Austin, Texas, L7 Informatics, provides software and services that enable synchronized solutions for cell and gene therapy companies. Specifically, L7’s novel Enterprise Science Platform (ESP) is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems. The company’s mission is to use this technology to accelerate discoveries and drive precision healthcare.

In this interview, Vasu Rangadass – President and CEO of L7 Informatics – and I explore the company’s origins, its unique ESP technology, future directions, and more. Enjoy! [Read more…]

“Vision For The Future” Takes On New Meaning As Doug Oliver, Founder of The Regenerative Outcomes Foundation, Shares What Lies Ahead In His Journey

By

I am honored to release this interview with Doug Oliver, Founder of the Regenerative Outcomes Foundation. Doug has an incredible story of being a stem cell patient, turned renowned advocate and consultant within the field of regenerative medicine. In this interview, we explore what inspired him to establish the Regenerative Outcomes Foundation, his awards and accolades within the field, the critical importance of advocacy work, and so much more. Enjoy! [Read more…]

Demand Peaks for AAOSCP’s May 2019 “Basic Science to Clinical Practice” Stem Cell Workshop

By

Never before has a workshop featured BM, SVF, UCB, Peptides, Cytokines and Exosomes under the same roof.

AAOSCPThe American Academy of Stem Cell Physicians (AAOSCP) is hosting a May 2019 conference that is filling up fast. With limited space available, medical practitioners who are seeking to learn skills and techniques for integrating regenerative medicine (RM) into their practice are encouraged to register immediately. [Read more…]

Rhemastem, Leveraging Stem Cells from Solid Tumors in the Race to Cure Colorectal Cancer

By

Headquartered in Monza, Italy, RhemaStem is a unique biotech company that specializes in developing innovative and effective drugs for colorectal cancer and other solid cancers. The company’s mission is to cure colorectal cancer and other solid cancers using its expertise in the area of cancer and normal stem cells. I had the distinct honour of interviewing Dr. Zeni of RhemaStem.

In this interview, we explore the founding of Rhemstem, its unique technology platform, intellectual property (IP), future directions, and more. Enjoy! [Read more…]

Thermo Fisher Scientific to Acquire Cell & Gene Therapy CMO Brammer Bio for $1.7B

By

Thermo Fisher Scientific Inc. (NYSE: TMO) has entered a definitive agreement to acquire Brammer Bio, a contract manufacturing organization (CMO) specializing in cell and gene therapies (CGT). Valued at approximately $1.7 billion in cash, the transaction represents one of the most lucrative acquisitions of a cell and gene therapy CMO to date. [Read more…]

BioInformant's World-Class Clients